A2 Biotherapeutics enters into collaboration agreement With Merck ; cell therapy for solid tumor Cancers


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ A2 Biotherapeutics enters into collaboration agreement With Merck ; cell therapy for solid tumor Cancers
Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize

A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, in which A2 will continue research and preclinical development of its undisclosed Tmod cell therapy candidate (its third candidate therapy), with the parties to co-fund A2’s clinical development and allogeneic manufacturing activities through Phase 1. Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1.

A2’s Tmod engineered T cells uniquely combine a potent activating mechanism to kill tumor cells with a blocking mechanism that protects normal cells from harm by exploiting the loss of genetic material in tumors. Tmod engineered T cells have the potential to make existing targets safer and more effective by protecting normal cells and delivering a more therapeutically effective dose to kill the tumor cells.

“In vitro studies have provided compelling evidence supporting the view that Tmod-based cell therapy can distinguish tumor cells from normal cells, across multiple tumor targets,” said Dr. Roger M. Perlmutter, President, Merck Research Laboratories. “We hope that the combined efforts of Merck Research Laboratories and A2 Biotherapeutics will enable the application of this ingenious approach to improve the treatment of patients suffering from refractory solid tumors.”

Under the agreement A2 will receive an upfront payment, and will be eligible for opt-in and milestone payments, plus royalties on sales of any approved product. A2 will also receive from Merck an equity investment and reimbursement of certain expenses. Merck has the option to designate a new Tmod program with increased economic terms.

“This transaction extends our cash runway on the heels of our successful $71.5M Series B in October. It also brings Merck’s immunotherapy and other expertise for the Tmod candidate especially in the later stages of development, manufacturing and commercialization and enables A2 to build allogeneic product development and manufacturing capabilities,” said Scott Foraker, President and CEO of A2 Biotherapeutics.

A2 will continue to pursue its first two Tmod product candidates using its autologous manufacturing to reduce the number of variables for clinical proof of concept and expedite timelines. A2 anticipates that the successful development of its allogeneic Tmod candidate therapy will enable subsequently developed allogeneic Tmod candidates.

Tags : #Merck #A2Biotherapeutics #SolidTumorCancer #TMod #ScottForaker #LatestPharmaNews #MerckCollaboratesA2Biotherapeutics

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026